Vogue Italia spotlights our co-founder Sophia Wang, and her unique perspective as an artist and writer whose creative practice guides her work as a biotech entrepreneur. See the full feature: vogue.it/article/mycowo…

Physicians and patients have long been waiting for something better than conven­tional ex vivo CAR‑T therapy, and Umoja Biopharma is finally bringing that wait to an end. More on our excitement around Umoja's significant milestone 👇 dcvc.com/news-insights/…

Welcome to the DCVC Bio portfolio, NILO! NILO Therapeutics is working to develop groundbreaking therapies for autoimmune and inflammatory diseases, building on pioneering research from Columbia's Zuker Lab. Read more on our investment in Endpoints News 👇 bit.ly/4doW6tI

Our CEO Chris Hart proposes a paradigm shift in how we approach oligonucleotide-based medicine development, emphasizing the need to understand the complex interplay between sequence and chemistry. Read more in Nucleic Acid Insights: insights.bio/nucleic-acid-i…

Obsessed with Farming Simulator? Sabanto has just the job for you👇 The future of farming is here! 🕹️🚜 bit.ly/4dKuP4Y

"The days of promising technology are behind us - be a builder." hubs.la/Q02LYsHZ0

🌐 According to the World Health Organization (WHO), major depressive disorder impacts approximately 280 million people globally, while schizophrenia affects about 24 million. To accelerate #clinicaldevelopment and bring new treatments to patients faster, we launched #digitaltwin generators for both

"Digital twins are the future of medicine. They basically replace our entire medical system; you basically turn medicine into a predictive science, you run experiments, and you optimize patients' treatments" — @charleskfisher in the ZDNET article, "How digital twins could save

Please welcome Serge Messerlian DCVC, to our Board of Directors! With extensive leadership in life sciences, Serge brings valuable expertise to support our mission of reimagining drug development through AI-enabled engineering of OBMs. brnw.ch/21wMua9

Great in-depth coverage from Allison DeAngelis STAT about our announcement of DCVC Bio III: $400 million in fresh capital to continue backing the next generation of companies building breakthrough data-driven life-science businesses.👇 bit.ly/47Q3qgw

Our second annual Deep Tech Opportunities Report is here, offering an extended look at deep tech and how we believe it can help build a future of abundance and resilience. We hope you enjoy it — and the possi­bil­i­ties it signals. dcvc.com/news-insights/…

We're thrilled to announce that thanks to the most forward-looking investors on the planet, we’ve raised over $700 million for a healthier planet and healthier lives, bringing our total funding closed over the last 2.5 years to over $1.6 billion 🌎🧬🌾 bit.ly/4eHLNl9

When one of your portfolio cos is moving toward commer­cial­izing what may be the most conse­quen­tial cancer therapeutic ever, you’re allowed to take a minute to feel excited. That's how we feel today having co-led Umoja Biopharma's $100m Series C! 🍾 dcvc.com/news-insights/…

Reishi is here! 🎉 Very exciting progress from MycoWorks, which continues to push the boundaries of sustainable design 👇 fashionunited.in/news/business/…

How is MycoWorks scaling its production and simultaneously doing R&D for new mycelium materials? Find out from CEO Matthew Scullin in a great Axios piece from Katie Fehrenbacher 👇 axios.com/pro/climate-de…

Creyon Bio names Serge Messerlian as CEO and appoints Kiersten Stead, PhD, to the Board. With revitalized leadership & AI-powered oligo tech, we're advancing therapies in CNS, neuromuscular, & immunologic diseases. creyonbio.com/latest-news/ #BiotechNews #AIinHealthcare

Augmented RNA reality is emerging! Creyon Bio has the ability to program­mat­i­cally engineer knowably safe and effective siRNAs, ASOs, and other oligo therapies to unlock a huge range of therapeutic advances👇 dcvc.com/news-insights/…